Tumor angiogenesis, a new target for cancer therapy;L'ANGIOGENESE TUMORALE: UNE NOUVELLE CIBLE THERAPEUTIQUE ANTICANCEREUSE

Medecine/Sciences

Volumn 13, Issue 12, 1997, Pages 1428-1434

  Gingras, Denis ^a   Béliveau, Richard ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BETA INTERFERON; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; METASTASIS; PATHOPHYSIOLOGY; PSORIASIS; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0030698670     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/574     Document Type: Review

References (27)

1. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31-6.
2. Lepage P, Gros P. La glycoprotéine P: de la résistance croisée aux médicaments au transport des lipides biliaires. Med Sri 1995 ; 11: 357-66.
3. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89-118.
4. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995 ; 333: 1757-63.
5. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid ana other disease. Nature Med 1095; 1: 27-31.
7. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-96.
8. Frelin C, Ladoux A, Bauters C. VEGF: médiateur de l'angiogenèse hypoxique. Med Sci 1997; 13: 886-91.
9. Rak J, Filmus J, Finkenzeller G, Grugel S, Marmé D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995; 14: 263-77.
10. Vandenbunder B, Fafeur V, Wernert N, Stéhelin D. Analyse moléculaire de l'angiogenèse tumorale. Med Sci 1994; 10: 516-27.
11. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
12. Wolf C, Lefebvre O, Rouyer N, Chenard M, Bellocq J, Rio M, Chambon P, Basset P. Protéases d'origine stromale et progression tumorale. Med Sci 1994; 10: 507-15.
13. Homandberg GA, Williams JE, Grant D, Schumacher B, Eisenstein R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol 1985; 120: 327-32.
14. Clapp C, Martial JA, Guzman RC, Rentier-Delrue F, Weiner RI. The 16 kDa N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993; 133: 1292-9.
15. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin : a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
16. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
17. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-82.
18. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
19. Folkman J, Watson K, Ingher D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
20. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
21. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
22. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. AntiCancer Drugs 1995; 6: 3-18.
23. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
24. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996; 2: 689-92.
25. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-53.
26. Parangi S, O'Reilly MS, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996; 93: 2002-7.
27. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease, Cancer Res 1992; 52: 6702-4.